Uterine leiomyomas are one of the most common gynecological conditions in women older than 30 years old, and its incidence is about 30% throughout the world. Despite their high incidence rate, pathophysiology of leiomyoma is still not well understood.
| INTRODUC TI ON
Uterine leiomyomas are one of the most common gynecological conditions in women older than 30 years old, and its incidence is about 30% throughout the world. Despite their high incidence rate, pathophysiology of leiomyoma is still not well understood. 1, 2 It has been proposed that genetic tendency, steroid hormone concentration, and fibrotic process which develop through the effect of growth factors, angiogenesis, and chromosome abnormalities are responsible for the development of leiomyomas. 3, 4 Leiomyomas are hormone-sensitive tumors. Estrogen and progesterone hormones and their receptors have a critical role in the formation and developmental processes of leiomyomas. Especially, estrogen plays a promoting role and is effective in leiomyoma proliferation. 5, 6 Estrogen binds specific nuclear receptors, which are estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), and exerts its effects on the target cell. 7 ERα and ERβ mRNA levels are higher in leiomyomas compared to those in myometrium. 8 ERα is an important intermediary in the signal transduction pathway and also a member of the steroid/ thyroid hormone superfamily of nuclear receptors. 9 The ERα gene located on chromosome 6q25 and contains eight exons and greater than 140 kilobases. The gene contains intron 1 polymorphisms XbaI and PvuII. 9, 10 It has been reported that these polymorphisms are associated with a large number of estrogen-related diseases, such as osteoarthritis, breast cancer, and endometriosis. ERα-mutant XbaI * G and PvuII * C alleles may be responsible for increased serum estradiol (E2) production. 10 Another factor that has a critical role in the development of leiomyoma is progesterone. 8 Studies suggested that mitotic activity increased in leiomyomas in the secretory phase of cycle and progesterone levels effects leiomyoma development. 11 There are two forms of progesterone receptor: receptor-A (PGR-A) and receptor-B (PGR-B).
PGR-A and PGR-B mRNAs were isolated in leiomyoma and myometrium tissues, and mRNA concentrations are higher in leiomyoma than in neighboring myometrium. 12 The PGR gene is located on chromosome 11q22-23, and several genetic variants were detected. The genetic variations can be listed in as PROGINS, rs10895068, rs561650, and rs608995. These variants are located on the hormone-binding domain encoding sequence of PROGINS gene. The PROGINS include a 306-bp Alu repeat insertion in intron G in the hormone-binding domain-encoding region of the gene.
13-15
Gene polymorphism studies could be useful and enlightening in multifactorial conditions such as leiomyoma. Polymorphisms of genes involved in synthesis and signalization of steroid hormones could be used as genetic markers in hormone-related conditions.
16,17
The purpose of our study was to analyze the effect of ERα-351 XbaI A/G-397 PvuII T/C and PGR PROGINS polymorphisms on leiomyoma development.
| MATERIAL AND ME THOD

| Study groups
The present study was carried out with patients who applied to 
| Genetic analysis
Genomic DNA (gDNA) was isolated from peripheral blood using Table 2 . The amplified products were run on a 3% agarose gel and examined under ultraviolet light.
| Statistical analysis
Statistical analyses were carried out using Open Epi Info Software groups, respectively. According to our data, PGR PROGINS polymorphism was not significant for genotype or allele frequencies in study groups (Table 4) . 
| RE SULTS
| D ISCUSS I ON
In the present study, genotype frequencies of estrogen receptor polymorphisms, ERα-351 XbaI A/G and ERα-397 PvuII T/C, and of PGR PROGINS polymorphisms, were investigated. A significant difference was not observed among leiomyoma patient and healthy control groups for ERα polymorphisms and allele distributions.
Moreover, frequencies of 159-bp T1 allele (wild type) and 465-bp T2
allele (PROGINS ALU insertion) were investigated in leiomyoma patient and control groups. The genotype frequencies of PGR PROGINS polymorphism were not significantly different in the study groups.
There are some studies investigating the relationship between leiomyoma development and estrogen receptor gene polymorphisms, and the results are contradictory. Such a study found no association between leiomyoma development and estrogen receptor α-397 PvuII T/C gene polymorphism in Caucasians. 18 On the other hand, another study on different races showed that leiomyoma development risk increased in Black or White women carrying these ERα polymorphisms while no increase was found in Hispanic women. 19 Massart et al 20 found different results for the association between leiomyoma development and ERα-351 XbaI A/G and ERα-397
PvuII T/C gene polymorphisms in two different studies conducted on Italian women. In the first study, showed an association in 119 patients between leiomyoma development and gene polymorphism.
In the second study where the patient number was increased to 413, 21 no association was found. As can be seen in these studies, an association between receptor gene polymorphism and leiomyoma Estrogen is usually the major stimulator of leiomyoma. However, biochemical, histological, and clinical evidence indicates that estrogen and progesterone have similar abilities to promote tumorigenesis. 27 Some investigators stressed that progesterone and PGR play significant roles in mitotic efficiency, growth factors and growth factor receptors. 28 In their studies on relations among progesterone receptor polymorphism and uterine leiomyoma, endometriosis and breast cancer, Govindan et al 29 suggested that PROGINS was a risk factor for breast cancer, but they did no t find any predisposing risk factor for uterine leiomyoma and endometriosis. Gomes et al 30 and PGR PROGINS polymorphisms and leiomyoma development.
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